메뉴 건너뛰기




Volumn 26, Issue 1, 2012, Pages 48-53

Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: A trial of the German Dermatologic Cooperative Oncology Group

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; HYALURONIC ACID;

EID: 83955162958     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04005.x     Document Type: Article
Times cited : (46)

References (24)
  • 1
    • 0033928865 scopus 로고    scopus 로고
    • Epidemiology of actinic keratoses and squamous cell carcinoma
    • Salasche SJ,. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42 (1 Pt 2): 4-7.
    • (2000) J Am Acad Dermatol , vol.42 , Issue.1 PART 2 , pp. 4-7
    • Salasche, S.J.1
  • 3
    • 0033940686 scopus 로고    scopus 로고
    • Clinical presentation of actinic keratoses and squamous cell carcinoma
    • Moy RL,. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42 (1 Pt 2): 8-10.
    • (2000) J Am Acad Dermatol , vol.42 , Issue.1 PART 2 , pp. 8-10
    • Moy, R.L.1
  • 4
    • 33745010916 scopus 로고    scopus 로고
    • Solar (actinic) keratosis is squamous cell carcinoma
    • DOI 10.1111/j.1365-2133.2005.07121.x
    • Ackerman AB, Mones JM,. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155: 9-22. (Pubitemid 43876387)
    • (2006) British Journal of Dermatology , vol.155 , Issue.1 , pp. 9-22
    • Ackerman, A.B.1    Mones, J.M.2
  • 5
    • 0035097541 scopus 로고    scopus 로고
    • Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis
    • Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumour angiogenesis and metastasis. Neoplasia 2001; 3: 53-61. (Pubitemid 32201610)
    • (2001) Neoplasia , vol.3 , Issue.1 , pp. 53-61
    • Gallo, O.1    Franchi, A.2    Magnelli, L.3    Sardi, I.4    Vannacci, A.5    Boddi, V.6    Chiarugi, V.7    Masini, E.8
  • 6
    • 29244449354 scopus 로고    scopus 로고
    • Prostaglandins and cancer
    • DOI 10.1136/gut.2004.047100
    • Wang D, Dubois RN,. Prostaglandins and cancer. Gut 2006; 55: 115-122. (Pubitemid 41820645)
    • (2006) Gut , vol.55 , Issue.1 , pp. 115-122
    • Wang, D.1    Dubois, R.N.2
  • 9
    • 34247333077 scopus 로고    scopus 로고
    • The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs)
    • DOI 10.1111/j.1365-2133.2007.07856.x
    • Fecker LF, Stockfleth E, Nindl I, et al. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol 2007; 156 (Suppl. 3): 25-33. (Pubitemid 46632508)
    • (2007) British Journal of Dermatology , vol.156 , Issue.SUPPL. 3 , pp. 25-33
    • Fecker, L.F.1    Stockfleth, E.2    Nindl, I.3    Ulrich, C.4    Forschner, T.5    Eberle, J.6
  • 10
    • 18844423259 scopus 로고    scopus 로고
    • Hyaluronic acid: A unique topical vehicle for the localized delivery of drugs to the skin
    • DOI 10.1111/j.1468-3083.2004.01180.x
    • Brown MB, Jones SA,. Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol 2005; 19: 308-318. (Pubitemid 40691707)
    • (2005) Journal of the European Academy of Dermatology and Venereology , vol.19 , Issue.3 , pp. 308-318
    • Brown, M.B.1    Jones, S.A.2
  • 11
    • 0029070913 scopus 로고
    • Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation
    • Hall CL, Yang B, Yang X, et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 1995; 82: 19-26.
    • (1995) Cell , vol.82 , pp. 19-26
    • Hall, C.L.1    Yang, B.2    Yang, X.3
  • 13
    • 0035659622 scopus 로고    scopus 로고
    • Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses
    • DOI 10.1046/j.1365-4362.2001.01324.x
    • Wolf JE Jr, Taylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-713. (Pubitemid 34023642)
    • (2001) International Journal of Dermatology , vol.40 , Issue.11 , pp. 709-713
    • Wolf Jr., J.E.1    Taylor, J.R.2    Tschen, E.3    Kang, S.4
  • 14
    • 0030841385 scopus 로고    scopus 로고
    • An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% Hyaluronic acid gel for the treatment of actinic keratoses
    • Rivers JK, McLean DI,. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997; 133: 1239-1242. (Pubitemid 27443816)
    • (1997) Archives of Dermatology , vol.133 , Issue.10 , pp. 1239-1242
    • Rivers, J.K.1    McLean, D.I.2
  • 15
    • 0037325491 scopus 로고    scopus 로고
    • Topical diclofenac in hyaluronan gel for the treatment of solar keratoses
    • DOI 10.1046/j.1440-0960.2002.00635.x
    • Gebauer K, Brown P, Varigos G,. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003; 44: 40-43. (Pubitemid 36246421)
    • (2003) Australasian Journal of Dermatology , vol.44 , Issue.1 , pp. 40-43
    • Gebauer, K.1    Brown, P.2    Varigos, G.3
  • 16
    • 7644224775 scopus 로고    scopus 로고
    • Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze)
    • Nelson C, Rigel D, Smith S, et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004; 3: 401-407.
    • (2004) J Drugs Dermatol , vol.3 , pp. 401-407
    • Nelson, C.1    Rigel, D.2    Smith, S.3
  • 18
    • 33646204466 scopus 로고    scopus 로고
    • Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp
    • Smith SR, Morhenn VB, Piacquadio DJ,. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006; 5: 156-159.
    • (2006) J Drugs Dermatol , vol.5 , pp. 156-159
    • Smith, S.R.1    Morhenn, V.B.2    Piacquadio, D.J.3
  • 20
    • 27744503544 scopus 로고    scopus 로고
    • Translating the science of quality of life into practice: What do dermatology life quality index scores mean?
    • Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-664.
    • (2005) J Invest Dermatol , vol.125 , pp. 659-664
    • Hongbo, Y.1    Thomas, C.L.2    Harrison, M.A.3
  • 22
    • 0033928866 scopus 로고    scopus 로고
    • Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis")
    • Cockerell CJ,. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol 2000; 42 (1 Pt 2): 11-17.
    • (2000) J Am Acad Dermatol , vol.42 , Issue.1 PART 2 , pp. 11-17
    • Cockerell, C.J.1
  • 23
    • 76349101673 scopus 로고    scopus 로고
    • Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses
    • Dirschka T, Bierhoff E, Pflugfelder A, et al. Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses. J Eur Acad Dermatol Venereol 2010; 24: 258-263.
    • (2010) J Eur Acad Dermatol Venereol , vol.24 , pp. 258-263
    • Dirschka, T.1    Bierhoff, E.2    Pflugfelder, A.3
  • 24
    • 57749206167 scopus 로고    scopus 로고
    • Development of a treatment algorithm for actinic keratoses: A European Consensus
    • Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18: 651-659.
    • (2008) Eur J Dermatol , vol.18 , pp. 651-659
    • Stockfleth, E.1    Ferrandiz, C.2    Grob, J.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.